Regeneron Files Q2 2024 10-Q

TL;DR

Regeneron's Q2 2024 10-Q is in: financials and operations updated.

AI Summary

Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter of 2024. Key financial figures and business segments are presented, reflecting the company's ongoing activities in the pharmaceutical sector.

Why It Matters

This filing provides investors and analysts with the latest financial health and operational performance of Regeneron, a major player in the biopharmaceutical industry.

Risk Assessment

Risk Level: low — This is a routine quarterly financial filing with no immediate or unusual risk indicators.

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Filer
• 20240630 (date) — Period of Report
• 20240801 (date) — Filing Date
• TARRYTOWN (location) — Business Address City
• NY (location) — Business Address State
• 10591 (postal_code) — Business Address Zip

FAQ

Filing Documents

• regn-20240630.htm (10-Q) — 2044KB
• regn-ex_311x06302024x10q.htm (EX-31.1) — 12KB
• regn-ex_312x06302024x10q.htm (EX-31.2) — 12KB
• regn-ex_32x06302024.htm (EX-32) — 7KB
• 0001804220-24-000028.txt ( ) — 7480KB
• regn-20240630.xsd (EX-101.SCH) — 36KB
• regn-20240630_cal.xml (EX-101.CAL) — 63KB
• regn-20240630_def.xml (EX-101.DEF) — 226KB
• regn-20240630_lab.xml (EX-101.LAB) — 478KB
• regn-20240630_pre.xml (EX-101.PRE) — 357KB
• regn-20240630_htm.xml (XML) — 1125KB

Financial Statements (unaudited)

Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations and Comprehensive Income 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 43 Item 4.

Controls and Procedures

Controls and Procedures 44 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 44 Item 1A.

Risk Factors

Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 78 I tem 5. O ther Information 78 Item 6. Exhibits 78 SIGNATURE PAGE 79 "Altibodies ," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD," "Inmazeb ," "Libtayo ," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," " Veloci-Bi ," " VelociGene ," " VelociHum ," " VelociMab ," " VelocImmune ," " VelociMouse ," " VelociSuite ," " VelociT ," "Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners. This report refers to products of Regeneron Pharmaceuticals, Inc., its collaborators, and other parties. Consult the product label in each territory for specific information about such products. Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements REGENERON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In millions, except per share data) June 30, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 1,920.7 $ 2,730.0 Marketable securities 7,888.3 8,114.8 Accounts receivable, net 5,717.1 5,667.3 Inventories 2,873.6 2,580.5 Prepaid expenses and other current assets 681.9 386.6 Total current assets 19,081.6 19,479.2 Marketable securities 7,722.4 5,396.5 Property, plant, and equipment, net 4,305.9 4,146.4 Intangible assets, net 1,102.2 1,038.6 Deferred tax assets 2,880.9 2,575.4 Other noncurrent assets 993.8 444.1 Total assets $ 36,086.8 $ 33,080.2 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 561.7 $ 606.6 Accrued expenses and other current liabilities 2,360.9 2,357.9 Deferred revenue 586.0 458.9 Total current liabilities 3,508.6 3,423.4 Long-term debt 1,983.6 1,982.9 Finance lease liabilities 720.0 720.0 Deferred revenue 205.6 126.7 Other noncurrent liabilities 1,463.2 854.1 Total liabilities 7,881.0 7,107.1 Stockholders' equity: Preferred Stock, par value $ .01 per share; 30.0 shares authorized; shares issued and outstanding - no ne — — Class A Stock, convertible, par value $ .001 per share; 40.0 shares authorized; shares issued and outstanding - 1.8 in 2024 and 2023 — — Common Stock, par value $ .001 per share; 320.0 shares authorized; shares issued - 134.8 in 2024 and 133.1 in 2023 0.1 0.1 Additional paid-in capital 12,316.9 11,354.0 Retained earnings 29,414.6 27,260.3 Accumulated other comprehensive loss ( 69.9 ) ( 80.9 ) Treasury Stock, at cost; 26.4 shares in 2024 and 25.5 shares in 2023 ( 13,455.9 ) ( 12,560.4 ) Total stockholders' equity 28,205.8 25,973.1 Total liabilities and stockholders' equity $ 36,086.8 $ 33,080.2 The accompanying notes are an integral part of the financial statements. 2 Table of Contents REGENERON PHARMACEUTICALS, INC.

View Full Filing

View this 10-Q filing on SEC EDGAR